Table 1.
Correlation of CerS6 expression with patient clinical characteristics
| Variable | Expression of CerS6 | Total | Χ2 | P | |
|---|---|---|---|---|---|
|
| |||||
| Low | High | ||||
| Group | |||||
| Serous Cystadenoma | 31 (88.57) | 4 (11.43) | 35 | ||
| Serous Ovarian cancer | 44 (40) | 66 (60) | 110 | 25.086 | 0.000 |
| Total | 75 (51.72) | 70 (48.28) | 145 | ||
| Age | |||||
| ≤ 50 | 15 (41.67) | 21 (58.33) | 36 | ||
| > 50 | 29 (39.19) | 45 (60.81) | 74 | 0.062 | 0.803 |
| Total | 44 (40) | 66 (60) | 110 | ||
| Lymph node metastasis | |||||
| Present | 8 (33.33) | 16 (66.67) | 24 | ||
| Absent | 36 (41.86) | 50 (58.14) | 86 | 0.568 | 0.451 |
| Total | 44 (40) | 66 (60) | 110 | ||
| Grade of Serous | |||||
| High | 33 (34.38) | 63 (65.63) | 96 | ||
| Low | 11 (78.57) | 3 (21.43) | 14 | 9.944 | 0.003 |
| Total | 44 (40) | 66 (60) | 110 | ||
| FIGO Stage | |||||
| I+II | 25 (52.1) | 23 (47.9) | 48 | ||
| III+IV | 19 (30.65) | 43 (69.35) | 62 | 5.181 | 0.023 |
| Total | 44 (40) | 66 (60) | 110 | ||
FIGO: The International Federation of Gynecology and Obstetrics.